Cargando…
Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90
Heteronemin, a marine sesterterpenoid-type natural product, possesses diverse bioactivities, especially antitumor effect. Accumulating evidence shows that heteronemin may act as a potent anticancer agent in clinical therapy. To fully understand the antitumor mechanism of heteronemin, we further expl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025191/ https://www.ncbi.nlm.nih.gov/pubmed/29890785 http://dx.doi.org/10.3390/md16060204 |
_version_ | 1783336227518283776 |
---|---|
author | Lee, Man-Gang Liu, Yi-Chang Lee, Yi-Lun El-Shazly, Mohamed Lai, Kuei-Hung Shih, Shou-Ping Ke, Seng-Chung Hong, Ming-Chang Du, Ying-Chi Yang, Juan-Cheng Sung, Ping-Jyun Wen, Zhi-Hong Lu, Mei-Chin |
author_facet | Lee, Man-Gang Liu, Yi-Chang Lee, Yi-Lun El-Shazly, Mohamed Lai, Kuei-Hung Shih, Shou-Ping Ke, Seng-Chung Hong, Ming-Chang Du, Ying-Chi Yang, Juan-Cheng Sung, Ping-Jyun Wen, Zhi-Hong Lu, Mei-Chin |
author_sort | Lee, Man-Gang |
collection | PubMed |
description | Heteronemin, a marine sesterterpenoid-type natural product, possesses diverse bioactivities, especially antitumor effect. Accumulating evidence shows that heteronemin may act as a potent anticancer agent in clinical therapy. To fully understand the antitumor mechanism of heteronemin, we further explored the precise molecular targets in prostate cancer cells. Initially, heteronemin exhibited potent cytotoxic effect against LNcap and PC3 prostate cancer cells with IC(50) 1.4 and 2.7 μM after 24 h, respectively. In the xenograft animal model, the tumor size was significantly suppressed to about 51.9% in the heteronemin-treated group in comparison with the control group with no significant difference in the mice body weights. In addition, the results of a cell-free system assay indicated that heteronemin could act as topoisomerase II (topo II) catalytic inhibitor through the elimination of essential enzymatic activity of topoisomerase IIα expression. We found that the use of heteronemin-triggered apoptosis by 20.1–68.3%, caused disruption of mitochondrial membrane potential (MMP) by 66.9–99.1% and promoted calcium release by 1.8-, 2.0-, and 2.1-fold compared with the control group in a dose-dependent manner, as demonstrated by annexin-V/PI, rhodamine 123 and Fluo-3 staining assays, respectively. Moreover, our findings indicated that the pretreatment of LNcap cells with an inhibitor of protein tyrosine phosphatase (PTPi) diminished growth inhibition, oxidative and Endoplasmic Reticulum (ER) stress, as well as activation of Chop/Hsp70 induced by heteronemin, suggesting PTP activation plays a crucial rule in the cytotoxic activity of heteronemin. Using molecular docking analysis, heteronemin exhibited more binding affinity to the N-terminal ATP-binding pocket of Hsp90 protein than 17-AAG, a standard Hsp90 inhibitor. Finally, heteronemin promoted autophagy and apoptosis through the inhibition of Hsp 90 and topo II as well as PTP activation in prostate cancer cells. Taken together, these multiple targets present heteronemin as an interesting candidate for its future development as an antiprostatic agent. |
format | Online Article Text |
id | pubmed-6025191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60251912018-07-09 Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 Lee, Man-Gang Liu, Yi-Chang Lee, Yi-Lun El-Shazly, Mohamed Lai, Kuei-Hung Shih, Shou-Ping Ke, Seng-Chung Hong, Ming-Chang Du, Ying-Chi Yang, Juan-Cheng Sung, Ping-Jyun Wen, Zhi-Hong Lu, Mei-Chin Mar Drugs Article Heteronemin, a marine sesterterpenoid-type natural product, possesses diverse bioactivities, especially antitumor effect. Accumulating evidence shows that heteronemin may act as a potent anticancer agent in clinical therapy. To fully understand the antitumor mechanism of heteronemin, we further explored the precise molecular targets in prostate cancer cells. Initially, heteronemin exhibited potent cytotoxic effect against LNcap and PC3 prostate cancer cells with IC(50) 1.4 and 2.7 μM after 24 h, respectively. In the xenograft animal model, the tumor size was significantly suppressed to about 51.9% in the heteronemin-treated group in comparison with the control group with no significant difference in the mice body weights. In addition, the results of a cell-free system assay indicated that heteronemin could act as topoisomerase II (topo II) catalytic inhibitor through the elimination of essential enzymatic activity of topoisomerase IIα expression. We found that the use of heteronemin-triggered apoptosis by 20.1–68.3%, caused disruption of mitochondrial membrane potential (MMP) by 66.9–99.1% and promoted calcium release by 1.8-, 2.0-, and 2.1-fold compared with the control group in a dose-dependent manner, as demonstrated by annexin-V/PI, rhodamine 123 and Fluo-3 staining assays, respectively. Moreover, our findings indicated that the pretreatment of LNcap cells with an inhibitor of protein tyrosine phosphatase (PTPi) diminished growth inhibition, oxidative and Endoplasmic Reticulum (ER) stress, as well as activation of Chop/Hsp70 induced by heteronemin, suggesting PTP activation plays a crucial rule in the cytotoxic activity of heteronemin. Using molecular docking analysis, heteronemin exhibited more binding affinity to the N-terminal ATP-binding pocket of Hsp90 protein than 17-AAG, a standard Hsp90 inhibitor. Finally, heteronemin promoted autophagy and apoptosis through the inhibition of Hsp 90 and topo II as well as PTP activation in prostate cancer cells. Taken together, these multiple targets present heteronemin as an interesting candidate for its future development as an antiprostatic agent. MDPI 2018-06-10 /pmc/articles/PMC6025191/ /pubmed/29890785 http://dx.doi.org/10.3390/md16060204 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lee, Man-Gang Liu, Yi-Chang Lee, Yi-Lun El-Shazly, Mohamed Lai, Kuei-Hung Shih, Shou-Ping Ke, Seng-Chung Hong, Ming-Chang Du, Ying-Chi Yang, Juan-Cheng Sung, Ping-Jyun Wen, Zhi-Hong Lu, Mei-Chin Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title | Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title_full | Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title_fullStr | Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title_full_unstemmed | Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title_short | Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90 |
title_sort | heteronemin, a marine sesterterpenoid-type metabolite, induces apoptosis in prostate lncap cells via oxidative and er stress combined with the inhibition of topoisomerase ii and hsp90 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025191/ https://www.ncbi.nlm.nih.gov/pubmed/29890785 http://dx.doi.org/10.3390/md16060204 |
work_keys_str_mv | AT leemangang heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT liuyichang heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT leeyilun heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT elshazlymohamed heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT laikueihung heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT shihshouping heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT kesengchung heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT hongmingchang heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT duyingchi heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT yangjuancheng heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT sungpingjyun heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT wenzhihong heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 AT lumeichin heteroneminamarinesesterterpenoidtypemetaboliteinducesapoptosisinprostatelncapcellsviaoxidativeanderstresscombinedwiththeinhibitionoftopoisomeraseiiandhsp90 |